Studies show that neuropeptide-receptor systems in the basolateral amygdala (BLA) play an important role in the pathology of anxiety and other mood disorders. Since GPR171, a recently deorphanized receptor for the abundant neuropeptide BigLEN, is expressed in the BLA, we investigated its role in fear and anxiety-like behaviors. To carry out these studies we identified small molecule ligands using a homology model of GPR171 to virtually screen a library of compounds. One of the hits, MS0021570_1, was identified as a GPR171 antagonist based on its ability to block (i) BigLEN-mediated activation of GPR171 in heterologous cells, (ii) BigLEN-mediated hyperpolarization of BLA pyramidal neurons, and (iii) feeding induced by DREADD-mediated activation of BigLEN containing AgRP neurons in the arcuate nucleus. The role of GPR171 in anxiety-like behavior or fear conditioning was evaluated following systemic or intra-BLA administration of MS0021570_1, as well as following lentiviral-mediated knockdown of GPR171 in the BLA. We find that systemic administration of MS0021570_1 attenuates anxiety-like behavior while intra-BLA administration or knockdown of GPR171 in the BLA reduces anxiety-like behavior and fear conditioning. These results indicate that the BigLEN-GPR171 system plays an important role in these behaviors and could be a novel target to develop therapeutics to treat psychiatric disorders.
INTRODUCTION
Mental health disorders such as anxiety and post-traumatic stress disorder affect~11% of the population (Silberberg et al, 2015) . Despite years of research, current treatments for these disorders are limited and associated with numerous side effects. Thus, alternative therapies for these disorders are needed. Neuropeptide receptors are ideally suited for the development of therapeutics due to their involvement in different physiological behaviors including fear, anxiety, depression, and pain. We recently identified GPR171 as the receptor for BigLEN, one of the most abundant neuropeptides in the brain (Fricker, 2010) , and found that the BigLEN-GPR171 system modulates feeding-related behaviors within the hypothalamus (Gomes et al, 2013) . However, not much is known about the role of BigLEN-GPR171 system in other brain regions and other physiological processes.
The Allen Brain Atlas shows expression of BigLEN and GPR171 in the basolateral amygdala (BLA) (Lein et al, 2007) . The BLA plays a critical role in anxiety-like behaviors and in memory acquisition, consolidation, and retrieval by processing affective information and attaching emotional significance to cues and events (Stamatakis et al, 2014) . Neuropeptide-receptor systems are thought to modulate these behaviors in the amygdala. For example, Neuropeptide Y (NPY), a peptide involved in regulation of feeding in the hypothalamus, has been shown to produce anxiolytic effects and lead to resilience after stress (Sajdyk et al, 2008; Desai et al, 2013; Christiansen et al, 2014) .
Since we find expression of BigLEN and GPR171 in the BLA, we hypothesized that this peptide-receptor system could play a role in regulating mood-related behaviors. To test this hypothesis, we identified a small molecule antagonist by in silico screening of a homology model. We used molecular and behavioral pharmacology and electrophysiology to characterize this compound within the BLA. In addition, we confirmed the physiological involvement of GPR171 in anxiety-like and fear behaviors using shRNAmediated reduction in GPR171 in this brain region. Our studies indicate that GPR171 represents a novel target for the development of novel therapeutics to treat psychiatric disorders.
MATERIALS AND METHODS

Subjects
Male C57bl/6 J or AgRP-IRES-Cre mice (Jackson Laboratories) were 8-12 weeks old at the beginning of the experiment. Food and water were available ad libitum except during testing. Mice were group housed (4-5 per cage) in a humidity and temperature-controlled room with a 12 h light/ dark cycle (on 0700-1900 hours). Testing took place between 0800 and 1600 hours. All procedures were approved by the Institutional Care and Use Committee at Icahn School of Medicine at Mount Sinai.
Surgical Procedures
Mice were anesthetized with ketamine/xylazine (100 mg/kg, i.p.). Control or GPR171 shRNA lentivirus (0.5 μl, rate of 0.1 μl/min, 10 − 9 (Gomes et al, 2013) ) was infused into the BLA (AP: − 1.7 mm, ML: ± 3 mm, DV: − 4.8 mm) using stereotaxical techniques (Paxinos and Franklin, 2001) . The injector was kept in place for an additional 2 min to prevent backflow. To selectively activate AgRP neurons a credependent adeno-associated virus excitatory DREADD (0.5 μl, rate of 0.1 μl/min, AAV8-hSyn-DIO-hM3Dq-mCherry; University North Carolina vector core, 10
) was bilaterally infused into the arcuate nucleus (AP: − 1.5 mm, ML: ± 0.3 mm, DV: − 5.9 mm) of AgRP-IRES-Cre mice. For microinjection studies, mice were bilaterally cannulated into the BLA (24 gauge, 6 mm). Injection cannulae were inserted and extended 1 mm past the guide cannula. Mice were allowed to recover 2 weeks prior to beginning behavioral testing. Microinjections of vehicle (10% DMSO, 10% Tween80 in saline) or MS0021570_1 (20 nmol/0.5 μl) were administered 0.5 μl over 1 min.
Behavioral Assays
Mice were habituated to the testing room 1 h prior to each experiment. Behaviors were videotaped and analyzed using Noldus EthoVision XT or by an experimenter blinded to the treatment groups. Mice were injected with MS0021570_1 (5 mg/kg, i.p.) 15 min prior to elevated plus maze, open field, forced swim, and contextual fear conditioning. For microinjection studies, MS0021570_1 was injected 10 min prior to testing and immediately following the contextual fear conditioning. A counterbalanced within-subjects design was used when appropriate (ie, battery of anxiety tests).
Food intake. Singly housed AgRP-IRES-Cre mice with creinducible DREADD in the arcuate nucleus received MS0021570_1 (3.5 mg/kg, i.p.) or vehicle (6% DMSO in saline) 15 min prior to CNO (1 mg/kg, i.p.) or saline injection. Food intake was measured at 1, 2, 4, and 8 h post injection.
Forced swim test. Mice were placed into a 4 l glass beaker with 2.5 l water (25 ± 1°C) for 6 min. Immobility was scored using a 5 s sampling method as previously published (Hodes et al, 2015) and the percentage of time spent immobile was reported.
Elevated plus maze. Contextual fear conditioning. Mice were placed into a chamber with steel rod flooring and white noise for 2 min, then received a 2 s shock (0.6 mA) followed by an additional 2 min with white noise. The following day mice were placed back into the same chamber and time spent freezing was measured for 5 min using a 5 s sampling method. A subset of mice was tested at 1 and 2 weeks post shock.
Immunohistochemistry
Immunohistochemistry was conducted as described previously (Wardman et al, 2016) . More details are in the Supplementary Material and Methods. Briefly, staining was performed on free-floating coronal slices (40 μm) containing BLA from 4% paraformaldehyde-perfused mice. Primary antibodies were used to detect GPR171 (1 : 250, Genetex rabbit) or GFP (1 : 500, mouse, Cell Signaling). Microscopy was performed at the Microscopy CORE at the Icahn School of Medicine at Mount Sinai using either Leica DM6000 or Leica SP5-DM confocal. Cannula placements were determined using injection of trypan blue and detection with a light microscope.
Current-Clamp Recordings
More details on slice preparation and electrophysiology in Supplementary Material and Methods. Briefly, slices containing BLA were prepared in high-sucrose cutting solution (in mM: 210.3 sucrose, 26.2 NaHCO 3 , 11 glucose, 4 MgCl 2 , 2.5 KCl, 1 NaH 2 PO 4 , 0.5 ascorbate, and 0.5 CaCl 2 ; − 2 to − 4°C). Slices were maintained in standard artificial cerebrospinal fluid (ACSF, in mM: 119 NaCl, 26.2 NaHCO 3 , 11 glucose, 2.5 KCl, 2 CaCl 2 , 2 MgCl 2 , and 1 NaH 2 PO 4 ) saturated with 5%CO 2 /95%O 2 .
Electrodes were 3-5 MΩ when filled with intracellular solution containing (in mM): 127.5 K-methanesulfonate, 10 HEPES, 5 KCl, 5 Na-phosphocreatine, 2 MgCl 2 , 2 Mg-ATP, 0.6 EGTA, and 0.3 NaGTP (pH 7.25; 285-300 mOsm). Pyramidal neurons in the BLA were visually identified based on morphology. Cells were maintained at − 70 mV with current injection (MultiClamp 700B, Molecular Devices, Sunnyvale, CA) and membrane potential was continuously recorded using a gap-free protocol in Clampex (Molecular Devices). For BigLEN experiments, a stable baseline was established (⩾3 min) in ACSF, followed by a switch to ACSF +100 nM BigLEN. Following equilibration to steady state, bath solution was changed to ACSF+100 nM BigLEN+1 μM antagonist (MS0021570_1); these solutions had a final concentration of 1 × protease inhibitor cocktail and 0.0001% DMSO. For small molecule agonist experiments, 1 μM agonist (MS0015203) was used in place of BigLEN; solutions for these experiments had a final concentration of 1 × protease inhibitor cocktail and 0.0002% DMSO. Solutions were delivered using a homemade gravity perfusion system. Data were sampled at 10 kHz and low pass filtered at 3 kHz. Traces were analyzed in Clampfit (Molecular Devices). Cell culture and transfections. CHO cells grown in F-12 medium containing 10% fetal bovine serum and 1 × penicillin-streptomycin were transfected with myc-tagged GPR171 along with a chimeric G α15/i3 protein using lipofectamine as per the manufacturer's protocol for experiments measuring intracellular Ca +2 levels. CHO cells were transfected with DYKDDDDK-tagged mGPR171 or mMT1A receptor constructs using lipofectamine and stable cell lines generated as described in the manufacturer's protocol.
Biochemical Assays
Homology modeling and in silico screening at GPR171. A homology model of mouse GPR171 based on the crystal structure of the phylogenetically related P2Y12 receptor (Gloriam et al, 2007; Kakarala and Jamil, 2014) corresponding to PDB code 4PXZ (Piccoli et al, 2014) was generated as described previously (Wardman et al, 2016 ). This homology model was used for in silico screening of small molecule ligands for GPR171 as described previously (Wardman et al, 2016) .
Measurement of intracellular Ca
+2 levels. These assays were carried out as described previously (Gomes et al, 2009; Gupta et al, 2010; Gomes et al, 2013) using CHO cells (40 000 cells per well) expressing myc-tagged mGPR171 along with a chimeric G α15/i3 protein treated with 1 μM BigLEN in the absence or presence of 10 μM of the 13 compounds from the screening library. Increases in intracellular Ca +2 levels were measured for~210 s at excitation 494 nm and emission 516 nm.
Membrane preparation. Membranes from rat hypothalamus were prepared as described previously (Gomes et al, 2003 (Gomes et al, , 2013 .
Binding assays. Tyr-BigLEN (200 μg) was iodinated using [ 125 I] and Pierce iodination reagent as described in the manufacturer's protocol (Thermo Scientific). The specific activity of the iodinated peptide was 65.3 Ci/mmol at the time of iodination (the radiolabelled peptide was used within 60 days of iodination). Binding assays were carried out as described previously (Gomes et al, 2003 (Gomes et al, , 2013 Rozenfeld et al, 2011) (Gupta et al, 2010; Rozenfeld et al, 2011; Gomes et al, 2013) using membranes from rat hypothalamus (10 μg) incubated for 1 h at 30°C with 1 μM BigLEN or DAMGO in the absence or presence of MS0021570_1 (0-10 μM), or with MS0015203, (0-10 μM final concentration) in the absence or presence of 10 μM MS0021570_1.
Determination of cAMP levels. CHO cells expressing either DYKDDDDK-tagged mGPR171, mP2Y12, or mMT1A receptor (10 000 cells per well), or homogenates from rat amygdala were pretreated for 30 min with 20 μM forskolin followed by treatment with either BigLEN (1 μM), MS0015203 (1 μM), MeSADP (100 nM), or melatonin (100 nM) in the absence or presence of MS0021570_1 (10 μM) for 30 min. cAMP levels were quantified using the HitHunter cAMP detection kit from DiscoveRx according to the manufacturer's protocol. Due to the size of tissue, homogenates of rat amygdala were used.
qRT-PCR. Brains were removed and 2 mm slices were taken~1 mm caudal from Bregma. Punches of BLA were taken using 1 ml pipette tip. RNA extraction and cDNA preparation was performed as described previously (Wardman et al, 2016) from BLA of mice expressing control or lentiviral shRNA targeting GPR171. Quantitative RT-PCR was performed at the Icahn School of Medicine at Mount Sinai qPCR core with ABI PRISM 7900HT detection system. Analysis was performed using the ΔΔC T method.
Data and statistical analyses. Results are expressed as the mean ± SE. Data comparing more than one group were analyzed using one-way ANOVAs or two-way ANOVAs (repeated measures when appropriate) followed by Fisher's LSD or Bonferroni's post hoc comparisons. Data comparing two groups were analyzed using two-tailed unpaired Student's t-tests. Significance was set at po0.05. Statistical analyses of data were generated by using Prism software (version 6.0; GraphPad Software).
RESULTS
Identification and Characterization of a Small Molecule Antagonist to GPR171
Using a homology model of GPR171 to virtually dock an inhouse library of chemical compounds, we previously identified 13 putative small molecule ligands that when tested in a cell-based assay measuring intracellular Ca +2 release in cells expressing GPR171 and a chimeric G 15/i3 GPR171 facilitates anxiety and fear EN Bobeck et al protein identified MS0015203 as a GPR171 agonist (Wardman et al, 2016) . To identify a receptor antagonist, we tested these compounds in the presence of BigLEN and found two of them (MS0021570_1 and MS0015917) to be antagonists as evidenced by significant (po0.05) attenuation of BigLEN-mediated increases in intracellular Ca +2 release (Figure 1a and b) . Displacement binding assays show that MS0021570_1 dose dependently and completely displaced radiolabeled BigLEN binding to hypothalamic membranes albeit with a lower affinity (~31-fold) compared to BigLEN ( Figure 1c) ; MS0015917 only partially (~37%) displaced radiolabeled BigLEN binding (Figure 1c) . Also, MS0016911 and MS0022269, two other compounds belonging to the same cluster as MS0021570_1 (that could be commercially purchased) were less potent and not able to displace radiolabeled BigLEN to the same extent as MS0021570_1 (Supplementary Table S1 ). Thus, we focused our characterization studies on MS0021570_1.
Characterization of MS0021570_1 as a Possible Selective Antagonist for GPR171
Next, we examined the properties of MS0021570_1 in the G-protein activity assay. MS0021570_1 dose dependently (f) MS0021570_1 (10 μM) attenuated BigLEN-(1 μM) mediated decreases in cAMP levels in CHO cells expressing GPR171. MS0021570_1 (10 μM) had no effect on MesADP-(100 nM) mediated decreases in cAMP levels in CHO cells expressing mP2Y12 receptor. **po0.01; ****po0.0001, one-way ANOVA. Data in a-f represent means ± SE (n = 3-6). ANOVA, analysis of variance; CHO, Chinese hamster ovary; ND, not detected; NS, not significant. Figure  1d and e). Interestingly, on its own MS0021570_1 did not exhibit agonistic activity and exhibited only a slight inverse agonistic activity at very-high concentrations (Figure 1d) . Moreover, MS0021570_1 did not antagonize the activity of an unrelated G-protein coupled receptor (μ-opioid receptor; Figure 1d ). MS0021570_1 also behaved as an antagonist in the inhibition of adenylyl cyclase activity since we found that MS0021570_1 significantly attenuated BigLEN-mediated decreases in intracellular cAMP levels (Figure 1f) . In contrast, in cells expressing the P2Y12 receptor (the receptor used for homology modeling), MS0021570_1 had no significant effect on its own or on the P2Y12 agonist (MesADP)-mediated decreases in cAMP levels (Figure 1f) . These results indicate that MS0021570_1 exhibits antagonistic activity at GPR171.
To assess the level of selectivity of MS0021570_1 for GPR171, the ligand was screened against a panel of 80 different membrane targets (including~70 GPCRs). The ability of MS0021570_1 to displace radioligand binding to each of the targets was tested at 10 μM concentration; at this concentration MS0021570_1 displaced o30% binding at these targets (Supplementary Figure S1A) , with the exception of melatonin 1A receptor (MT1AR). We directly examined the effect of MS0021570_1 on MT1AR and found that MS0021570_1 exhibited a 1000-fold lower potency in the cAMP assays and did not further affect MT1AR agonistmediated decreases in cAMP (Supplementary Figure S1B and C). These results suggest that MS0021570_1 is a GPR171 antagonist at low (submicromolar) doses and at very-high doses it has the potential to function as an MT1AR agonist.
In vivo Characterization of GPR171 Antagonist
To study MS0021570_1's antagonistic activity in vivo, we examined if it has the ability to inhibit BigLEN-/GPR171-mediated effects. For this, we used an excitatory DREADD to specifically examine the effect of MS0021570_1 to block the activation of AgRP neurons; BigLEN has been shown to be coexpressed in neurons that contain AgRP/NPY in the arcuate nucleus and activation of these neurons is likely to lead to the release of BigLEN (Wardman et al, 2011 ). MS0021570_1 did not alter feeding over 8 h in mice on normal chow diet (Supplementary Figure S2A; t (19) = 1.54; p = 0.14). We expressed the excitatory DREADD in the AgRP neurons (Supplementary Figure S2B) and examined the effect of the antagonist on CNO-mediated increase in food intake. As shown previously, activating AgRP neurons with CNO led to a significant increase in feeding compared to saline controls (Krashes et al, 2011) ; Supplementary Figure S2C ; F (1, 123) = 26.82; po0.001) and this correlated with the number of neurons expressing the DREADD (Supplementary Figure S2D ; r = 0.56, po0.05). Importantly, we find that pretreatment with the GPR171 antagonist, MS0021570_1 significantly attenuated this CNO-mediated increase in food intake (Supplementary Figure S2E; t (19) = 3.24; po0.001).
In order to understand the role of BigLEN-GPR171 system in other behaviors, MS0021570_1 was administered to mice followed by psychiatric-and memory-related tests. Systemic showing that the administration of the agonist had no effect on the majority of the behaviors tested suggest a potentially high basal tone (BigLEN and other ProSAASderived peptides are among the most abundant neuropeptides in the brain). In contrast we find that systemic administration of the GPR171 antagonist reduces AgRP neuron-induced feeding and some anxiety-like behaviors (but has no effect on depression-like behaviors or fear conditioning), suggesting a role for this receptor in modulating anxiety-like behaviors. A potential site of action for the GPR171 antagonist to regulate anxiety-like behavior is the BLA since it exhibits GPR171 expression (Figure 3a) . To test whether blocking GPR171 in the BLA alters behavior, MS0021570_1 was injected bilaterally into BLA; cannula placements are shown in Figure 3b . Intra-BLA administration of MS0021570_1 led to an increase in open arm time on the elevated plus maze (Figure 3c ; t (29) = 2.10; po0.05) although there was no effect on locomotor activity during this test (Supplementary Figure S3A ; t 24 = 1.61, p = 0.12). Interestingly, when administered before and immediately following fear conditioning, MS0021570_1 significantly attenuated freezing measured 24 h later (Figure 3d ; t (20) = 2.18; p = 0o0.05). There was not a significant difference between vehicle and MS0021570_1 when injected outside of BLA on the elevated plus maze (Supplementary Figure S3B ; t (13) = 0.15, p = 0.88) or contextual fear conditioning (Supplementary Figure S3C; t (9) = 1.11, p = 0.30; placements marked with X in Figure 3b ). Behavioral differences between systemic and intra-BLA administration of MS0021570_1 (ie, no significance observed upon systemic administration) could be due to the pharmacokinetic and pharmacodynamic properties of the drug. Further studies are needed to characterize the GPR171 antagonist. Nevertheless, these results support the notion that antagonism of GPR171 in the BLA leads to a significant decrease in anxiety-like behavior and also in contextual fear conditioning.
Knockdown of GPR171 in the BLA
If the behavioral effects observed following the administration of MS0021570_1 into the BLA are due to blocking the activity of GPR171, then knocking down these receptors should result in similar effects. To assess this, lentivirus shRNA targeting GPR171 or control lentivirus were Figure S4E ; t (16) = 0.11, p = 0.91). These results further support a role for GPR171 in modulating some anxiety-like behaviors.
When tested in fear conditioning, mice with a knockdown of GPR171 in the BLA freeze immediately following a single foot shock similar to controls (Figure 4d; F (1, 30) = 0.85, p = 0.36) indicating similar initial fear responses in both groups. However, 24 h following the shock, mice with BLA GPR171 knockdown show reduced freezing compared to controls (Figure 4e ; t (32) = 2.71, po0.05). This attenuation in contextual fear conditioning was found to be maintained for up to 2 weeks (Figure 4f; F (1, 32) = 5.04, po0.05). Together, these results suggest that GPR171 in BLA regulates some anxiety-like behaviors and contextual fear conditioning.
Characterization of GPR171 in the BLA
Given that GPR171 signals through G i/o in the hypothalamus (Gomes et al, 2013) , we hypothesized that GPR171 activation may lead to membrane hyperpolarization within the BLA. We tested this by continuously recording the membrane potential of BLA pyramidal neurons while both applying either BigLEN or a small molecule GPR171 agonist (MS0015203). We observed a significant hyperpolarization in response to both BigLEN (Figure 5a ; − 73.6 ± 1.5 mV, F (2,10) = 10.84, po0.004) and MS0015203 (Figure 5b ; − 73.5 ± 0.6 mV, F (2,14) = 21.27, po0.0001) compared to baseline (BigLEN, − 69.8 ± 0.5 mV; MS0015203, − 70.2 ± 0.2 mV). Upon addition of the GPR171 antagonist (MS0021570_1) in the presence of either BigLEN or MS0015203, we observed a return to baseline-like potentials (BigLEN+MS0021570_1, − 69.5 ± 0.4 mV; MS0015203 +MS0021570_1, − 69.4 ± 0.4 mV). We also found that 1 μM BigLEN and 1 μM MS0015203 cause inhibition of cAMP levels, which is blocked by application of pertussis toxin (Figure 5c ). Immunohistochemical analysis showed that GPR171 is found on vGlut2-and GAD67-positive neurons within the BLA (Supplementary Figure S5) . These results indicate that GPR171 is coupled to Gαi/o, which leads to membrane potential hyperpolarization following GPR171 agonist application on pyramidal neurons, however GPR171 is found on both excitatory and inhibitory neurons.
DISCUSSION
In this study, we show a role for the BigLEN-GPR171 system in fear and anxiety-like behaviors using a small molecule antagonist, MS0021570_1 and viral knockdown of GPR171. To identify the antagonist of GPR171, we used the crystal structure of a phylogenetically related receptor (P2Y12), to generate a homology model of GPR171 and virtually Mice tested on contextual fear conditioning were placed into a novel chamber for 2 min followed by a foot shock. In the 2 min post shock, mice with GPR171 knockdown in the BLA showed similar freezing as controls. (e) Mice were placed back into the chamber 24 h later and freezing response was measured for 5 min. Mice with GPR171 knockdown in BLA (n = 15) showed an attenuation of freezing compared to controls (n = 19). (f) Reduced freezing behavior in GPR171 knockdown mice (n = 8) compared to controls (n = 10) is seen at 1 and 2 weeks post shock. Scale bars = 10 μm *po0.05; ***po0.001. BLA, basolateral amygdale; mRNA, messenger RNA; qRT, quantitative real-time; shRNA, short hairpin RNA.
screened for putative receptor ligands. This approach has been successfully used to identify novel ligands with unique structures that bind to a given receptor, such as antagonists to melanin-concentrating hormone receptor 1 (Cavasotto et al, 2008) and allosteric modulators of mGluR5 (Anighoro et al, 2015) . Thus, the crystal structure of a receptor or the homology model of a receptor based on the crystal structure of a closely related receptor can be used to identify ligands by virtual screening (Stockert and Devi, 2015) . We previously used this strategy to identify MS0015203 as an agonist targeting GPR171 (Wardman et al, 2016) ; in this study a similar strategy was used to identify MS0021570_1 as an antagonist. The advantage of such an approach is the unbiased nature of ligand identification as well as the possibility of identifying molecules with novel scaffolds that could be used for modifying the hits to lead to identification of compounds that serve as invaluable tools for the pharmacological characterization of GPCRs. In order to characterize the specificity of MS0021570_1, we subjected it to a screen consisting of~80 different membrane proteins and among them MS0021570_1 was found to bind to only one other GPCR, MT1AR receptor. However, further characterization revealed that only at high concentration MS0021570_1 could function as an agonist of this receptor. Thus, it is possible that a portion of the behavioral effects observed with this ligand are partially due to its agonistic effects at MT1AR. However, this is unlikely since localization studies (autoradiography with 125 I radiolabeled melatonin) have revealed that this receptor is not expressed in the amygdala (Morgan et al, 1994) -the focus of the current study. Furthermore, our electrophysiological data with pyramidal BLA neurons show that MS0021570_1 antagonizes the effects of the small molecule agonist MS0015203 that does not exhibit binding to melatonin receptors (Wardman et al, 2016) . Finally, the observation that knockdown of GPR171 in the BLA produces behavioral effects similar to those seen upon administration of MS0021570_1 supports that this compound mediates its effects via GPR171.
The identification of MS0021570_1 as a selective antagonist was useful in exploring the role of GPR171 in anxietylike behaviors and in fear memories. It is well established that the amygdala is important for the acquisition, consolidation, and retrieval of fear memories and the maintenance of maladaptive behaviors such as anxiety (Maren et al, 2013) . Specifically, the BLA integrates sensory information and plays a central role in responding to fearful stimuli and the maintenance of contextual fear memories (Kochli et al, 2015) . The activity of the BLA is tightly regulated by a combination of excitatory glutamatergic and inhibitory GABAergic signals. The pyramidal neurons in the BLA are glutamatergic (Carlsen, 1988; Smith and Pare, 1994) , while local circuit interneurons are GABAergic (McDonald and Augustine, 1993) . Studies show that acute and chronic stress cause an increase in excitability of BLA pyramidal neurons (Hetzel and Rosenkranz, 2014; Rau et al, 2015) , and decreasing BLA excitability causes a reduction in anxiety-like behaviors (Silberman et al, 2010) . This is the first study to show that activation of GPR171 in the BLA leads to hyperpolarization of pyramidal neurons. It is also possible that GPR171 could modulate anxiety and fear via different subregions of the amygdala. Further studies are needed to determine how GPR171 alters excitability of these neurons and whether it is a presynaptic or postsynaptic mechanism. Our behavioral studies show that both antagonist administration and knockdown of GPR171 in BLA leads to attenuation of anxiety-like behavior and fear conditioning. Given that we found that GPR171 is found on GAD67-positive neurons in addition to the vGlut-positive pyramidal neurons, it is likely that GPR171 antagonist microinjection and knockdown in the BLA hit both populations of neurons. It will be important for future studies to knockdown GPR171 in a cell type-specific manner to elucidate the role of GPR171 in these behaviors.
The BLA is part of a larger circuitry that modulates fear and anxiety-like behaviors, which includes reciprocal projections from the medial prefrontal cortex (mPFC) and ventral hippocampus (vHPC) (Felix-Ortiz et al, 2013; Maren et al, 2013) as well as projections to the central amygdala (Gafford and Ressler, 2016) . Since antagonizing or knocking down GPR171 in the BLA has effects on anxiety-like behaviors and fear conditioning, it would be important for future studies to investigate the involvement of BigLEN and GPR171 in mPFC, vHPC, and central amygdala in fear and anxiety-like behaviors. The origin of fibers that contain BigLEN that act on pyramidal cells within the BLA is unknown. Given colocalization of BigLEN with NPY in the hypothalamus (Wardman et al, 2011) , it is possible that they are colocalizaed in other brain regions as well. Recent studies have shown that NPY projections into the BLA originate from multiple regions, which seem to regulate fear conditioning (Leitermann et al, 2016) . It is possible that NPY and BigLEN within the BLA are working in opposition to maintain homeostasis, for example, BigLEN release increases anxiety and NPY decreases anxiety.
Neuropeptides and their receptors play a role in modulating fear and anxiety-like behaviors in the BLA including NPY, PACAP, corticotrophin releasing factor (Hashimoto et al, 2001; Otto et al, 2001; Tasan et al, 2010; Cipriano et al, 2016) . Our data show that within the BLA the BigLEN-GPR171 system also plays a role. Support for this also comes from peptidomic analysis that detect BigLEN in several key brain regions involved in fear and anxiety-like behaviors, including amygdala, hippocampus, and prefrontal cortex (Zhang et al, 2008) . A previous study in ProSAAS (precursor of BigLEN) knockout mice show a decrease in locomotor activity, which was attributed to altered anxiety (Morgan et al, 2010) . However, we do not see a change in activity following our antagonist treatment or knockdown of GPR171. This difference can be explained by the multiple other neuropeptides that are missing in the ProSASS knockout mice (ie, PEN, SAAS) in addition to increases in compensatory systems. Further studies mapping the localization and function of BigLEN and GPR171 throughout the brain would help in understanding how this system modulates fear and anxiety-like behaviors.
Taken together these results suggest that the BigLEN-GPR171 system facilitates anxiety and fear conditioning. Systemic, intra-BLA administration of the GPR171 antagonist or knockdown of BLA GPR171 in the BLA causes a reduction in some anxiety-like behaviors and in fear conditioning. Anxiety and fear conditioning are complicated behaviors involving multiple brain regions, but disrupting GPR171 function within the BLA is sufficient to block the output of these behaviors. In conclusion, the BigLEN-GPR171 system is a new system that contributes to a variety of physiological functions including feeding, fear, and anxiety-like behaviors. This exciting new research expands our knowledge of neuropeptides in these behaviors.
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